Greater central subfield thickness and better visual acuity at baseline are associated with longer time to resolution of diabetic macular edema, shows study.
Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration
Faricimab, a new drug for nAMD, offers patients similar benefits at 16-week intervals as aflibercept at eight-week intervals, a study shows.